Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Chemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab as First-line Therapy in MSS Unresectable Metastatic Colorectal Cancer: a Prospective, Single-center, Single-arm Trial

NCT06415851 is registered in ClinicalTrials.gov with Zhangfa Song as lead sponsor.

NCT NCT06415851
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06415851 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Chemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab as First-line Therapy in MSS Unresectable Metastatic Colorectal Cancer: a Prospective, Single-center, Single-arm Trial
Lead sponsor
Zhangfa Song
Phase
Phase 2
Overall status
Unknown status
Start date
June 1, 2024
Completion date
May 30, 2026
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer, mss